ENTERO Entero Healthcare Solutions Q4 FY25 results (Jan–Mar 2025) and concall
Entero Healthcare Solutions Limited reported a strong Q4 and full year FY25, achieving significant milestones including crossing ₹5,000 crores in revenue and ₹100 crores in PAT. The company demonstrated robust organic growth of 16% for the full year and expanded its EBITDA margins to 3.4%. Management provided optimistic guidance for FY26, targeting over 30% revenue growth and 4%+ EBITDA margins, alongside a commitment to positive operating cash flow for the full year.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|
| Revenue | 1,301 | 1,359 | 1,339 |
| EBITDA | 42 | 50 | 49 |
| Net profit | 26 | 29 | 31 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
